Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia

被引:65
作者
Stevens, SJC
Verkuijlen, SAWM
Hariwiyanto, B
Harijadi
Fachiroh, J
Paramita, DK
Tan, IB
Haryana, SM
Middeldorp, JM
机构
[1] Free Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands
[2] Antoni Van Leeuwenhoek Hosp, Dept Otolaryngol Head & Neck Surg, Amsterdam, Netherlands
[3] Gadjah Mada Univ, Yogyakarta, Indonesia
关键词
D O I
10.1128/JCM.43.7.3066-3073.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in Southeast Asia and is strongly associated with Epstein-Barr virus (EBV). We investigated the primary diagnostic value of circulating EBV DNA and anti-EBV immunoglobulin G (IgG) and IgA levels in Indonesian NPC patients (n = 149). By a 213-bp Epstein-Barr virus nuclear antigen 1 (EBNA1)-based real-time LightCycler PCR, 72.5% of patients were positive for EBV DNA in whole blood, with 29.5% having levels above a previously determined clinical cutoff value (COV) of 2,000 EBV DNA copies/ml, the upper level in healthy carriers. In a 99-bp LightCycler PCR, 85.9% of patients were positive and 60.4% had levels above the COV. This assay quantified a significantly higher EBV load than the 213-bp PCR assay (P < 0.0001), suggesting that circulating EBV DNA is fragmented. Using data from 11 different studies, we showed a significant inverse correlation between PCR amplicon size and the percentage of patients positive for circulating EBV DNA (Spearman's rho = -0.91; P < 0.0001). EBV DNA loads were unrelated to anti-EBV IgG or IgA levels, as measured by VCA-p18 and EBNA1-specific synthetic peptide-based enzyme-linked immunosorbent assays. The presence of circulating tumor cells was assessed by amplification of BamHI-A rightward frame 1 (BARF1) mRNA, a viral oncogene abundantly expressed in EBV-carrying carcinomas but virtually absent from EBV-associated lymphomas. Despite high EBV DNA loads and the presence of EBNA1 and human U1A small nuclear ribonucleoprotein mRNA, BARF1 mRNA was never detected in blood. We conclude that amplicon size significantly influences EBV DNA load measurement in NPC patients. The circulating EBV DNA load is independent of serological parameters and does not reflect intact tumor cells. The primary diagnostic value of the EBV DNA load for the detection of NPC is limited.
引用
收藏
页码:3066 / 3073
页数:8
相关论文
共 70 条
  • [21] Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases
    Hayes, DP
    Brink, AATP
    Vervoort, MBHJ
    Middeldorp, JM
    Meijer, CJLM
    van den Brule, AJC
    [J]. JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1999, 52 (02): : 97 - 103
  • [22] EPSTEIN-BARR VIRUS-SPECIFIC IGA SERUM ANTIBODIES AS AN OUTSTANDING FEATURE OF NASOPHARYNGEAL CARCINOMA
    HENLE, G
    HENLE, W
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1976, 17 (01) : 1 - 7
  • [23] Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo
    Hochberg, D
    Middeldorp, JM
    Catalina, M
    Sullivan, JL
    Luzuriaga, K
    Thorley-Lawson, DA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (01) : 239 - 244
  • [24] Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy - The potential role of quantitative analysis of circulating Epstein-Barr virus DNA
    Hong, RL
    Lin, CY
    Ting, LL
    Ko, JY
    Hsu, MM
    [J]. CANCER, 2004, 100 (07) : 1429 - 1437
  • [25] HSIAO JR, 2000, CANCER, V94, P723
  • [26] HU LF, 1993, ONCOGENE, V8, P1575
  • [27] *INT AG RES CANC, 1997, EPSTEION BARR KAPOSI, V70
  • [28] Diagnostic value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carcinoma patients
    Kondo, S
    Horikawa, T
    Takeshita, H
    Kanegane, C
    Kasahara, Y
    Sheen, TS
    Sato, H
    Furukawa, M
    Yoshizaki, T
    [J]. CANCER SCIENCE, 2004, 95 (06): : 508 - 513
  • [29] AVOIDING FALSE POSITIVES WITH PCR
    KWOK, S
    HIGUCHI, R
    [J]. NATURE, 1989, 339 (6221) : 237 - 238
  • [30] Leung SF, 2003, CLIN CANCER RES, V9, P3431